SCHEMBL943034

SCHEMBL943034

O=C(Nc1ccc(-c2nc3ccccc3[nH]2)cc1)Nc1ccc(-c2nc3ccccc3[nH]2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 8/20 1.00
MMP2 P08253 3/20 0.75
MMP9 P14780 3/20 0.75
MMP8 P22894 3/20 0.75
MMP13 P45452 3/20 0.75
KDM4E B2RXH2 3/20 0.70
NPC1 O15118 2/20 0.67
TP53 P04637 2/20 0.67
MAPT P10636 2/20 0.67
HPGD P15428 2/20 0.67
RAB9A P51151 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
HSD17B10 Q99714 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
MEN1 O00255 1/20 0.65
ALDH1A1 P00352 1/20 0.65
POLB P06746 1/20 0.65
KMT2A Q03164 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6533676 1.00 HPSE (1.00) HPSEMMP2MMP9MMP8MMP13
SCHEMBL6532513 0.93 HPSE (0.87) HPSEMMP2MMP9MMP8MMP13
SCHEMBL6506352 0.93 HPSE (0.87) HPSEMMP2MMP9MMP8MMP13
SCHEMBL6503052 0.93 HPSE (0.87) HPSEMMP2MMP9MMP8MMP13
SCHEMBL6506260 0.91 MMP2 (0.93) HPSEMMP2MMP9MMP8MMP13
SCHEMBL6529592 0.89 HPSE (1.00) HPSEMMP2MMP9MMP8MMP13
SCHEMBL6530058 0.89 NPC1 (0.83) HPSEMMP2MMP9MMP8MMP13
SCHEMBL6528065 0.89 HPSE (0.79) HPSEMMP2MMP9MMP8MMP13
SCHEMBL2244714 0.88 HPSE (0.79) HPSEMMP2MMP9MMP8MMP13
SCHEMBL7851030 0.88 HPSE (0.79) HPSEMMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250204515-A1 Heparanase Inhibition for Graft Protection UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2025-06-26 US claimed
WO-2023175581-A1 HEPARANASE INHIBITION FOR GRAFT PROTECTION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-09-21 WO claimed
EP-2543396-B1 ARTIFICIAL SKIN SHISEIDO CO LTD (JP) 2019-04-10 EP claimed
EP-3381906-A1 COMPOUNDS FOR USE AS HEPARANASE INHIBITORS Leadiant Biosciences SA (CH) 2018-10-03 EP claimed
US-8871505-B2 Artificial skin SHISEIDO COMPANY, LTD. (JP) 2014-10-28 US claimed
US-20250204515-A1 Heparanase Inhibition for Graft Protection UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2025-06-26 US disclosed
US-20250041189-A1 STEM CELL PROLIFERATION PROMOTER SHISEIDO COMPANY, LTD. (JP) 2025-02-06 US disclosed
EP-4442811-A1 STEM CELL PROLIFERATION PROMOTER Shiseido Company, Ltd. (JP) 2024-10-09 EP disclosed
EP-3878970-B1 LAMININ 511 PRODUCTION PROMOTER, BASAL EPIDERMAL LAYER STABILIZER AND/OR SCREENING METHOD FOR AGENT TO MINIMIZE REDUCTION IN OR PROMOTE INCREASE IN EPIDERMAL STEM CELLS SHISEIDO CO LTD (JP) 2024-09-11 EP disclosed
CN-118202039-A Stem cell proliferation promoter 株式会社资生堂 2024-06-14 CN disclosed
US-20230404885-A1 EPIDERMAL STEM CELL PROLIFERATION-PROMOTING AGENT SHISEIDO COMPANY, LTD. (JP) 2023-12-21 US disclosed
WO-2023175581-A1 HEPARANASE INHIBITION FOR GRAFT PROTECTION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-09-21 WO disclosed
EP-2543396-A1 ARTIFICIAL SKIN Shiseido Company, Ltd. (JP) 2013-01-09 EP disclosed
US-20130006355-A1 ARTIFICIAL SKIN SHISEIDO COMPANY, LTD. 2013-01-03 US disclosed
US-20120328719-A1 EXTERNAL PREPARATION FOR SKIN SHISEIDO COMPANY, LTD. 2012-12-27 US disclosed
EP-2484359-A1 HEPARANASE ACTIVITY INHIBITOR SHISEIDO CO., LTD. (JP) 2012-08-08 EP disclosed
US-20120183481-A1 HEPARANASE ACTIVITY INHIBITOR SHISEIDO COMPANY, LTD. (JP) 2012-07-19 US disclosed
EP-2295028-A1 PREPARATION FOR PREVENTING OR AMELIORATING WRINKLES, TO BE TAKEN ORALLY, THROUGH INJECTION, OR THROUGH EXTERNAL APPLICATION TO SKIN, AND COSMETIC METHOD Shiseido Company, Ltd. (JP) 2011-03-16 EP disclosed
US-20110020477-A1 ORAL PREPARATION, INJECTION PREPARATION, EXTERNAL SKIN PREPARATION AND COSMETIC METHOD FOR PREVENTING OR IMPROVING WRINKLES SHISEIDO COMPANY, LTD. 2011-01-27 US disclosed
WO-2005042495-A1 (BENZIMIDAZOL-2-YL)-PHENYL-PHENYL-UREA COMPOUNDS AND METHODS FOR INHIBITING HEPARANASE ACTIVITY IMCLONE SYSTEMS INCORPORATED (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250204515-A1 Heparanase Inhibition for Graft Protection HPSE, ENGASE, HPN HPSE 1/4885MMP2 62/4885MMP9 190/4885
US-20230404885-A1 EPIDERMAL STEM CELL PROLIFERATION-PROMOTING AGENT MKI67, KRT18, KIT HPSE 609/4885MMP2 2511/4885MMP9 3240/4885
US-20250041189-A1 STEM CELL PROLIFERATION PROMOTER PCNA, IGFBP2, TCF12 HPSE 237/4885MMP2 2180/4885MMP9 648/4885
US-20120183481-A1 HEPARANASE ACTIVITY INHIBITOR HPSE, HEXA, ENGASE HPSE 1/4885MMP2 24/4885MMP9 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.